The Oncology Institute, Inc.
TOI
$4.49
$0.030.67%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.53% | 17.64% | 21.33% | 22.29% | 23.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.53% | 17.64% | 21.33% | 22.29% | 23.31% |
| Cost of Revenue | 17.96% | 20.54% | 28.24% | 30.57% | 30.11% |
| Gross Profit | 15.18% | 3.19% | -9.36% | -11.65% | -4.31% |
| SG&A Expenses | -7.90% | -7.70% | -5.30% | -4.11% | -5.75% |
| Depreciation & Amortization | 9.34% | 8.03% | 7.05% | 12.19% | 27.58% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.97% | 12.44% | 17.98% | 19.45% | 18.14% |
| Operating Income | 26.27% | 16.22% | 0.08% | -4.93% | 4.54% |
| Income Before Tax | 7.95% | 11.88% | 22.19% | 6.45% | -17.91% |
| Income Tax Expenses | 26.82% | -- | -- | -252.81% | 27.82% |
| Earnings from Continuing Operations | 7.90% | 11.79% | 22.16% | 6.75% | -18.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.90% | 11.79% | 22.16% | 6.75% | -18.10% |
| EBIT | 26.27% | 16.22% | 0.08% | -4.93% | 4.54% |
| EBITDA | 30.18% | 18.86% | 0.85% | -4.21% | 7.11% |
| EPS Basic | 14.45% | 13.82% | 23.34% | 7.47% | -18.04% |
| Normalized Basic EPS | 19.91% | 18.92% | 5.36% | -27.87% | -60.15% |
| EPS Diluted | 13.73% | 13.41% | 22.90% | 14.89% | 11.31% |
| Normalized Diluted EPS | 19.91% | 18.92% | 5.36% | -27.87% | -62.19% |
| Average Basic Shares Outstanding | 8.64% | 2.62% | 1.92% | 1.43% | 1.17% |
| Average Diluted Shares Outstanding | 8.64% | 2.62% | 1.92% | 1.43% | -1.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |